Esperion Therapeutics (FRA:0ET) Change In Payables And Accrued Expense : €30.0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Esperion Therapeutics Change In Payables And Accrued Expense?

Esperion Therapeutics's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was €-5.1 Mil. It means Esperion Therapeutics's Accounts Payable & Accrued Expense declined by €5.1 Mil from Dec. 2023 to Mar. 2024 .

Esperion Therapeutics's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was €28.2 Mil. It means Esperion Therapeutics's Accounts Payable & Accrued Expense increased by €28.2 Mil from Dec. 2022 to Dec. 2023 .

Esperion Therapeutics Change In Payables And Accrued Expense Historical Data

The historical data trend for Esperion Therapeutics's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Esperion Therapeutics Change In Payables And Accrued Expense Chart

Esperion Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Payables And Accrued Expense

Get a 7-Day Free Trial

-5.45

21.26

-24.05

9.08

28.22

Esperion Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Payables And Accrued Expense	Get a 7-Day Free Trial															-6.75	11.14	11.46	12.56	-5.13

Esperion Therapeutics Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €30.0 Mil.

Esperion Therapeutics Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Esperion Therapeutics's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Esperion Therapeutics (FRA:0ET) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Esperion Therapeutics Inc (FRA:0ET) » Definitions » Change In Payables And Accrued Expense

Comparable Companies

Traded in Other Exchanges

ESPR:USA

Address

3891 Ranchero Drive, Suite 150, Ann Arbor, MI, USA, 48108

Website

https://www.esperion.com

Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment.

Esperion Therapeutics (FRA:0ET) Headlines

No Headlines